Navigation Links
Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery

SEATTLE, May 3 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative joint function and motion and reduce postoperative pain. Omeros plans to present these additional data tomorrow in its webcast presentation at the Deutsche Bank Health Care Conference at 2:50 p.m. EDT and, for those not attending, has provided the clinical trial results below.

About the Phase 2 Trial of OMS103HP

The Phase 2 clinical trial was a prospective, multicenter, double-blind, randomized, vehicle-controlled study. Of the 161 patients who were enrolled and treated, 143 patients met the predetermined surgical and data collection criteria and were included in the data analysis (71 OMS103HP and 72 vehicle). There were no significant differences in demographic characteristics between the two treatment groups.

Pain scores in the immediate 24-hour period and up to seven days postoperatively were measured using a validated, 100-point, visual analog scale (VAS). Range of motion assessments were made at baseline and day seven postoperatively. The protocol was amended to collect patient self reports using the Knee Injury and Osteoarthritis Outcome Score (KOOS), which consists of five subscale scores: symptoms, pain, activities of daily living, sport and recreation function, and knee-based quality of life. The KOOS subset consisted of 70 subjects (33 OMS103HP and 37 vehicle). OMS103HP was well tolerated, and adverse events were more frequent in the vehicle group.

Clinically relevant benefits included the following:

  • The mean VAS pain scores within the first 24 hours following discharge from the recovery room demonstrated more pain in the vehicle group at the 2, 4, 6, 8 and 12-hour postoperative assessments. Averaged mean VAS scores over time for the first 24-hour postoperative period were 33.98 for OMS103HP and 38.35 for vehicle (p= 0.212). The repeated measures model analysis yielded a statistically significant result that indicates the profile difference between the OMS103HP and vehicle groups for the VAS pain score varied over time (p=0.004, e.g., the peak difference was observed at eight hours with VAS scores of 37.5 for OMS103HP and 47.3 for vehicle).
  • At the Day 7 assessment, OMS103HP and vehicle groups differed with respect to the assessment of passive flexion without pain (p=0.022; mean degree of flexion 121.6 versus 115.1, respectively). The proportion of subjects achieving flexion of greater than or equal to 95 (93.0% vs 85.0%), 110 (80.3% vs 68.1%) and 125 (p=0.001, 56.3% vs 29.1%) degrees at Day 7 was greater for the OMS103HP group.
  • The KOOS subscale scores all achieved the 0.05 level of significance (symptoms, p=0.046; pain, p=0.017; sport and recreation function, p<0.001; and knee-based quality of life, p=0.015) with the exception of activities of daily living (p=0.070). All the scores showed a sustained and consistent treatment effect through Day 90.
  • Subjects treated with OMS103HP were approximately two times more likely than vehicle-treated subjects to be in the highest quartile (i.e., greater than or equal to 75th percentile) of each of the sport and recreation subscale and overall KOOS scores (averaged across all five subscales). Conversely, vehicle-treated subjects were approximately two times more likely than OMS103HP-treated subjects to be in the lowest quartile (i.e., less than or equal to 25th percentile) of each of the sport and recreation subscale and overall KOOS scores.

"We are pleased with the outcome of this study, and believe that these data bode well for OMS103HP and our ongoing Phase 3 program evaluating the drug in arthroscopic ACL reconstruction. We look forward to reporting data from those trials later this year," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.

"Following knee arthroscopy for the treatment of a torn meniscus, patients have a highly variable return to normal function and especially work and sports performance," stated William E. Garrett, Jr., M.D., Ph.D., professor of orthopaedic surgery at Duke University Medical Center. "The efficacy observed in this study is clear from its series of objective measures and reliable subjective measures of knee function and pain. Further, this study demonstrates that treatment on the day of surgery alone continued to provide functional improvements at one and three months postoperatively. This should benefit both patients and surgeons."

About OMS103HP

OMS103HP is being developed for use during arthroscopic surgery to improve postoperative joint motion and function and reduce postoperative pain. Designed to preemptively inhibit inflammation, OMS103HP is injected into standard arthroscopic irrigation solutions and perfused through the joint in low concentrations during surgery. It is currently being evaluated in a Phase 3 clinical program for anterior cruciate ligament (ACL) surgery and has also completed a Phase 2 clinical trial for meniscectomy surgery. If approved, OMS103HP would be the first commercially available drug delivered directly to the surgical site to improve function following arthroscopic surgery.

About Meniscectomy Surgery

Arthroscopic meniscectomy is a minimally invasive surgical procedure used to treat a torn meniscus cartilage in the knee. Only the torn segment of the meniscus is removed. Postoperative recovery to normal function may take months. Approximately four million arthroscopic operations were performed in the United States in 2006, including 2.6 million knee arthroscopy operations.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction platform, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR (G-protein coupled receptor) program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's ability to announce the results from its Phase 3 clinical trials of its lead product candidate later this year. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2009. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
2. Daniel K. Spiegelman Elected to Board of Directors of Omeros
3. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
4. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
7. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
8. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
9. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
10. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
11. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
Post Your Comments:
(Date:12/6/2016)... is bringing their 100% all-natural lice removal service to ... 13 th Street was specifically chosen to make treatment convenient ... goal is to ease parents, stress and bring their lives back ... back to class without skipping a beat. The best part is ... whole family," Licenders President Adie Horowitz states. ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC announced ... recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 and ... same target on B cells as Rituxan and maintains ... but is also involved in tumor targeting, engagement of ... effect. The results of the study (abstract #95954) were ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
Breaking Medicine Technology:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):